All In Biotech

Drug Trial Radar · NCT07619833

To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

510

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of initial combination therapy with DWP16001 and DWC202518 compared to DWP16001 monotherapy and DWC202518 monotherapy in patients with Type 2 Diabetes Mellitus

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • DWP16001Drug

    DWP16001 0.3mg, Tablets, Orally, Once daily

  • DWC202518Drug

    DWC202518, Tablets, Orally, Once daily

  • Placebo of DWP16001Drug

    DWP16001 placebo-matching tablets

  • Placebo of DWC202518Drug

    DWC202518 placebo-matching tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c at Week 24 from Baseline after RandomizationTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kangbuk Samsung Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.